Potential therapeutic effects of GS-441524 and GC376 in cats with feline infectious peritonitis

Omid Nekouei; Sophie St-Hilaire; Pak Chun Hui; Karen Chan; Isabel Sumyi Chan; Sum Yuet Lorraine Ngan; Yion Chan; Ka Po Chung; Sunguk Hong; Hiu Man Chan; Hoi Lam Iris Or; Fong Yuen Chan; Hei Tung Yim; Vanessa R. Barrs

doi:10.18849/ve.v7i1.522

Potential therapeutic effects of GS-441524 and GC376 in cats with feline infectious peritonitis

Omid Nekouei^*
, Sophie St-Hilaire
, Pak Chun Hui
, Karen Chan
, Isabel Sumyi Chan
, Sum Yuet Lorraine Ngan
, Yion Chan
, Ka Po Chung
, Sunguk Hong
, Hiu Man Chan
, Hoi Lam Iris Or
, Fong Yuen Chan
, Hei Tung Yim
, Vanessa R. Barrs

^*Corresponding author for this work

Jockey Club College of Veterinary Medicine and Life Sciences

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

5 Citations (Scopus)

278 Downloads (CityUHK Scholars)

Abstract

PICO question
In cats with feline infectious peritonitis (FIP), does treatment with the nucleoside analogue GS-441524 or the protease inhibitor GC376, compared to supportive measures alone, lead to longer survival times?

Clinical bottom line

Category of research question
Treatment

The number and type of study designs reviewed
Five studies, including four uncontrolled interventional studies and one case-series were critically reviewed

Strength of evidence
Moderate

Outcomes reported
The reviewed studies collectively provide moderate evidence in support of the application of GS-441524 or GC376 to extend the survival time of cats suffering from feline infectious peritonitis

Conclusion
While these antiviral drugs are considered the most likely options for FIP treatment, more robust evidence should be obtained through well-designed randomised controlled trials to verify the observed positive effects in treating various forms of the disease and the potential long-term side effects. However, the ethical dilemmas of conducting double blinded placebo-controlled trials, which by necessity include untreated cats with an invariably fatal disease are recognised

Original language	English
Number of pages	12
Journal	Veterinary Evidence
Volume	7
Issue number	1
Online published	2 Feb 2022
DOIs	https://doi.org/10.18849/ve.v7i1.522
Publication status	Published - 2022

Publisher's Copyright Statement

This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

Access Output

10.18849/ve.v7i1.522

79125344.pdfFinal Published version, 428 KBLicence: CC BY

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{3674825fcab447f5b7e344deb086a86f,

title = "Potential therapeutic effects of GS-441524 and GC376 in cats with feline infectious peritonitis",

abstract = "PICO question In cats with feline infectious peritonitis (FIP), does treatment with the nucleoside analogue GS-441524 or the protease inhibitor GC376, compared to supportive measures alone, lead to longer survival times? Clinical bottom line Category of research question Treatment The number and type of study designs reviewed Five studies, including four uncontrolled interventional studies and one case-series were critically reviewed Strength of evidence Moderate Outcomes reported The reviewed studies collectively provide moderate evidence in support of the application of GS-441524 or GC376 to extend the survival time of cats suffering from feline infectious peritonitis Conclusion While these antiviral drugs are considered the most likely options for FIP treatment, more robust evidence should be obtained through well-designed randomised controlled trials to verify the observed positive effects in treating various forms of the disease and the potential long-term side effects. However, the ethical dilemmas of conducting double blinded placebo-controlled trials, which by necessity include untreated cats with an invariably fatal disease are recognised",

author = "Omid Nekouei and Sophie St-Hilaire and Hui, \{Pak Chun\} and Karen Chan and Chan, \{Isabel Sumyi\} and Ngan, \{Sum Yuet Lorraine\} and Yion Chan and Chung, \{Ka Po\} and Sunguk Hong and Chan, \{Hiu Man\} and Or, \{Hoi Lam Iris\} and Chan, \{Fong Yuen\} and Yim, \{Hei Tung\} and Barrs, \{Vanessa R.\}",

year = "2022",

doi = "10.18849/ve.v7i1.522",

language = "English",

volume = "7",

number = "1",

}

TY - JOUR

T1 - Potential therapeutic effects of GS-441524 and GC376 in cats with feline infectious peritonitis

AU - Nekouei, Omid

AU - St-Hilaire, Sophie

AU - Hui, Pak Chun

AU - Chan, Karen

AU - Chan, Isabel Sumyi

AU - Ngan, Sum Yuet Lorraine

AU - Chan, Yion

AU - Chung, Ka Po

AU - Hong, Sunguk

AU - Chan, Hiu Man

AU - Or, Hoi Lam Iris

AU - Chan, Fong Yuen

AU - Yim, Hei Tung

AU - Barrs, Vanessa R.

PY - 2022

Y1 - 2022

N2 - PICO question In cats with feline infectious peritonitis (FIP), does treatment with the nucleoside analogue GS-441524 or the protease inhibitor GC376, compared to supportive measures alone, lead to longer survival times? Clinical bottom line Category of research question Treatment The number and type of study designs reviewed Five studies, including four uncontrolled interventional studies and one case-series were critically reviewed Strength of evidence Moderate Outcomes reported The reviewed studies collectively provide moderate evidence in support of the application of GS-441524 or GC376 to extend the survival time of cats suffering from feline infectious peritonitis Conclusion While these antiviral drugs are considered the most likely options for FIP treatment, more robust evidence should be obtained through well-designed randomised controlled trials to verify the observed positive effects in treating various forms of the disease and the potential long-term side effects. However, the ethical dilemmas of conducting double blinded placebo-controlled trials, which by necessity include untreated cats with an invariably fatal disease are recognised

AB - PICO question In cats with feline infectious peritonitis (FIP), does treatment with the nucleoside analogue GS-441524 or the protease inhibitor GC376, compared to supportive measures alone, lead to longer survival times? Clinical bottom line Category of research question Treatment The number and type of study designs reviewed Five studies, including four uncontrolled interventional studies and one case-series were critically reviewed Strength of evidence Moderate Outcomes reported The reviewed studies collectively provide moderate evidence in support of the application of GS-441524 or GC376 to extend the survival time of cats suffering from feline infectious peritonitis Conclusion While these antiviral drugs are considered the most likely options for FIP treatment, more robust evidence should be obtained through well-designed randomised controlled trials to verify the observed positive effects in treating various forms of the disease and the potential long-term side effects. However, the ethical dilemmas of conducting double blinded placebo-controlled trials, which by necessity include untreated cats with an invariably fatal disease are recognised

U2 - 10.18849/ve.v7i1.522

DO - 10.18849/ve.v7i1.522

M3 - RGC 21 - Publication in refereed journal

SN - 2396-9776

VL - 7

JO - Veterinary Evidence

JF - Veterinary Evidence

IS - 1

ER -

Potential therapeutic effects of GS-441524 and GC376 in cats with feline infectious peritonitis

Abstract

Publisher's Copyright Statement

Access Output

Other Access Options

Permanent Link

Fingerprint

Cite this